CRBU Live signals | Maximize Profits with Getagraph.com

BUY 101402 min ago

@ $6.80

Issued: 14 Feb 2024 @ 14:06

Return: -43.38%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 2.45 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	937 371
Average Volume	1.62M
Market Cap	347.71M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.390 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.79
ATR14	$0.00800 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	O'byrne Jason	Buy	153 000	Option to purchase Common Stock
2024-02-20	O'byrne Jason	Buy	33 000	Common Stock
2024-02-20	Mcclung Barbara G	Buy	33 000	Common Stock
2024-02-20	Mcclung Barbara G	Buy	153 000	Option to purchase Common Stock
2024-02-20	Khan Ruhi Ahmad	Buy	153 000	Option to purchase Common Stock

INSIDER POWER
93.19
Last 96 transactions
Buy: 4 096 718 \| Sell: 409 985

Volume Correlation

Long: 0.26 (neutral)

Short: -0.14 (neutral)

Signal:(50.995) Neutral

Caribou Biosciences, Inc. Correlation

10 Most Positive Correlations
GLSI	0.945
ARVL	0.935
MICS	0.932
SATL	0.931
SXTC	0.931
NRXP	0.931
CSSE	0.93
STIM	0.927
GMVD	0.926
JAGX	0.924

10 Most Negative Correlations
LSCC	-0.951
PPYAU	-0.929
PDFS	-0.927
SNPS	-0.927
HEWG	-0.923
SMH	-0.922
SNSR	-0.922
MCHP	-0.921
INSE	-0.919
CCRC	-0.919

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Caribou Biosciences, Inc. Correlation - Currency/Commodity

0.19
( neutral )

0.00
( neutral )

0.74
( moderate )

-0.18
( neutral )

Caribou Biosciences, Inc. Financials

Annual	2023
Revenue:	$34.48M
Gross Profit:	$30.95M (89.78 %)
EPS:	$-1.380

Q4	2023
Revenue:	$3.56M
Gross Profit:	$1.58M (44.52 %)
EPS:	$-0.390

Q3	2023
Revenue:	$23.66M
Gross Profit:	$21.56M (91.10 %)
EPS:	$-0.120

Q2	2023
Revenue:	$3.76M
Gross Profit:	$2.63M (70.01 %)
EPS:	$-0.480

Financial Reports:

No articles found.

Caribou Biosciences, Inc.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.